Hemato Oncology Testing Market Global Trends, Market Share, Industry Size, Growth, Opportunities, and Market Forecast 2019 to 2029 Global Hemato Oncology Testing Market is estimated to value over USD 4.6 billion by 2029 end and register a CAGR of over 13.8% during the forecast period 2019 to 2029. The number of patients suffering from blood and tumour diseases is soaring high and that has been the primary reason for the Hemato oncology market to grow significantly. An increasing prevalence of haematological cancer, establishing collaborations for developing new assays and growing awareness with respect to personalized medicines. Furthermore, the rise in the geriatric population in recent times is another integral factor that drives the global hemato oncology market. However, uncertain reimbursement in different regions is expected to impede market growth. Request a Sample Report @ https://www.futurewiseresearch.com/requestsample.aspx?id=2276&page=requestsample Insights on Global Hemato Oncology Testing Market: 1. By Region • North America • Europe • Asia Pacific • Rest of the World North America dominated the global market in 2018. However, the Asia Pacific region is anticipated to witness a soaring market growth during the forecast period owing to the ever-increasing patient population and key market players focussing on expanding their businesses in the region are some important driving factors for the market growth. 2. By Product & Service Type • Services • Assay Kits The services segment dominated the market in 2018 owing to a soaring prevalence of leukemia, myeloma cancers and non-Hodgkin lymphoma. 3. By Cancer Type • Leukemia • Acute Myeloid Leukemia • Acute Lymphocytic Leukemia • Lymphoma • Non-Hodgkin Lymphoma • Hodgkin Lymphoma • Others Acute myeloid leukemia dominates the global market owing to a lack of early diagnosis of leukemia with limited options available for treatment. Furthermore, growing awareness regarding checking the status of minimal residual disease in patients suffering from acute myeloid leukemia is another integral factor that supports positive market growth. 4. By Technology • PCR • NGS • IHC • Cytogenetics • Others NGS is expected to witness a substantial growth during the forecast period due to its advantages like sensitivity and specificity. Purchase a Copy & Ask For Discount: https://www.futurewiseresearch.com/requestsample.aspx?id=2276&page=askfordiscount Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants Thermo Fischer Scientific Inc. provides profiling solutions for haematological malignancy using CytoScan HD Suite which is an extensive cytogenetic analysis of myeloid and lymphoid cancer samples. This test comprehensively covers the deletions, amplifications and loss of heterozygosity (LOH), ploidy changes and chromothripsis. The entire process from collecting nucleic acid samples to obtaining final results takes three days which is an added advantage considering how difficult it is to analyse and test these samples. Key Market Players: • F. Hoffmann-La Roche Ltd. • Abbott Laboratories • Thermo Fisher Scientific Inc. • Illumine Inc. • Molecular MD • Invivoscribe Inc. FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the hemato oncology testing market by region, by product & service type, by cancer type, by technology • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific and rest of the world • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions Inquire further details about this report at: [email protected] About FutureWise Research: We specialise in high-growth niche markets, assuring flexibility, agility and customised solutions for our clients. Through in-depth market insights and consultancy, we present our clients with the tools they need to be at the forefront of their industry – a position secured for far more than the near future. Contact Us: Company Name: FutureWise Research Contact Person: Vinay Thaploo Email: [email protected] Phone: +44 141 628 9353 / +1 970 279 4295 City: Leeds Country: United Kingdom Website: www.futurewiseresearch.com
Global Hemato Oncology Testing Market is estimated to value over USD 4.6 billion by 2029 end and register a CAGR of over 13.8% during the forecast period 2019 to 2029. The number of patients suffering from blood and tumour diseases is soaring high and that has been the primary reason for the Hemato oncology market to grow significantly.
© Copyright 2024 Paperzz
